Trial reportBritish journal of clinical pharmacology2003
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.
Trial report in British journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Co-administration of St. John's wort and hormonal contraceptives: a systematic review.Contraception · 2016Pooled it
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.Drugs · 2009Pooled it
- The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.British journal of clinical pharmacology · 2006Pooled it
- Interaction of St John's wort with conventional drugs: systematic review of clinical trials.BMJ (Clinical research ed.) · 2004Pooled it
- St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.European journal of clinical pharmacology · 2009Trial
- The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.British journal of clinical pharmacology · 2005Trial
- Hyperforin as a Multifunctional Specialized Metabolite of Natural Origin for Chronic Diseases: From Molecular Mechanisms to Clinical Translation.Current issues in molecular biology · 2026Review
- A drug-drug interaction study to evaluate the effects of strong CYP3A4 inducer on the pharmacokinetics of segesterone acetate and ethinyl estradiol in a contraceptive vaginal system.Contraception and reproductive medicine · 2025Article
- Clinical relevance of St. John's wort drug interactions revisited.British journal of pharmacology · 2020Review
- PXR as a mediator of herb-drug interaction.Journal of food and drug analysis · 2018Review
- Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.Evidence-based complementary and alternative medicine : eCAM · 2017Review
- Neuroprotective Activity of Hypericum perforatum and Its Major Components.Frontiers in plant science · 2016Review
- A survey of the use of complementary medicine by a self-selected community group of Australian women with polycystic ovary syndrome.BMC complementary and alternative medicine · 2014Article
- Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).EXCLI journal · 2014Review
- A survey describing the use of complementary therapies and medicines by women attending a family planning clinic.BMC complementary and alternative medicine · 2013Article
- Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi.The protein journal · 2012Article
- Drug interactions with herbal medicines.Clinical pharmacokinetics · 2012Review
- Concomitant use of prescription medications and dietary supplements in menopausal women: an approach to provider preparedness.Maturitas · 2011Review
- Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.The AAPS journal · 2009Review
- Which medications used in paediatric practice have demonstrated natural health product-drug interactions?: Part A: Evidence-based answer and summary.Paediatrics & child health · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsBreakthrough bleeding or even unwanted pregnancies have been reported in women during concomitant therapy with oral contraceptives and St John's wort extract. The aim of the present study was to investigate the effects of St John's wort extract on oral contraceptive therapy with respect to ovarian activity, breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel.
methodsEighteen healthy females were treated with a low-dose oral contraceptive (0.02 mg ethinyloestradiol, 0.150 mg desogestrel) alone (control cycle) or combined with 300 mg St John's wort extract given twice daily (cycle A) or three times daily (cycle B). Ovarian activity was assessed by measuring follicle maturation and serum oestradiol and progesterone concentrations. The number of breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel were assessed under steady-state conditions.
resultsDuring concomitant administration of low-dose oral contraceptive and St John's wort, there was no significant change in follicle maturation, serum oestradiol or progesterone concentrations when compared with oral contraceptive treatment alone. However, significantly more subjects reported intracyclic bleeding during cycles A (13/17 (77%), P < 0.015) and cycle B (15/17 (88%), P < 0.001) than with oral contraceptives alone (6/17 (35%)). The AUC(0,24 h) and Cmax of ethinyloestradiol remained unchanged during all study cycles, whereas the AUC(0,24 h) and Cmax of 3-ketodesogestrel decreased significantly from 31.2 ng ml-1 h to 17.7 ng x ml-1 h (43.9%; 95% confidence interval (CI) -49.3, -38.5, P = 0.001) and from 3.6 ng x ml -1 to 3.0 ng x ml -1(17.8%; CI -29.9, -5.7, P = 0.005), respectively, during cycle A and by 41.7% (CI -47.9, -35.6; P = 0.001) and by 22.8% (CI -31.2, -13.3; P < 0.001) during cycle B respectively, compared with the control cycle.
conclusionsThere was no evidence of ovulation during low-dose oral contraceptive and St John's wort extract combination therapy, but intracyclic bleeding episodes increased. Bleeding irregularities may adversely effect compliance to oral contraceptives and together with St John's wort-induced decreases in serum 3-ketodesogestrel concentrations, enhance the risk of unintended pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.